Cathie Wood Trims $3.3 Million in Top Tech Stock

This article first appeared on GuruFocus.

Cathie Wood’s ARK Invest trimmed its Meta Platforms (NASDAQ:META) position on Monday, selling roughly $3.36 million worth of shares while putting fresh capital into a group of biotechnology companies.

ARK sold 4,520 Meta shares through the ARK Innovation ETF. Based on Meta’s closing price of $742.96, the transaction was worth about $3.36 million.

The sale is notable because ARK had aggressively added to Meta in September, suggesting the latest move may represent profit-taking or portfolio rebalancing rather than a wholesale change in conviction.

Meta shares surged about 25% in September, helped partly by investor enthusiasm around the company’s expanding AI strategy.

That includes Muse, Meta’s AI assistant designed to handle complex, multistep tasks such as booking travel, sending emails and completing transactions. Meta also introduced Muse Wonder, a more advanced family of AI models that CEO Mark Zuckerberg said pushes the company closer to the frontier of artificial intelligence.

While trimming Meta, ARK was active on the buy side in biotech.

The firm purchased roughly $2.56 million of Alamar Biosciences, around $2.34 million of CRISPR Therapeutics, $2.16 million of Freenome and $2.13 million of Guardant Health.

ARK also added shares of Nurix Therapeutics, Intellia Therapeutics and Beam Therapeutics.

The firm separately sold about $4.49 million of DraftKings across two of its ETFs.

Investor Takeaway

I think the most important thing here is not that Cathie Wood suddenly turned bearish on Meta.

The timing suggests something more nuanced.

ARK had been buying Meta heavily before a strong September rally, so selling a relatively modest $3.36 million position after a 25% monthly gain could simply reflect portfolio discipline.

At the same time, ARK is rotating capital toward biotech names where valuations and upside potential may look more asymmetric.

That fits Wood’s broader strategy of backing disruptive technologies across multiple industries rather than remaining overly concentrated in one winner.

For Meta investors, I would focus less on this single ARK trade and more on AI monetization, Muse adoption, advertising growth and whether Meta can turn its expanding AI ecosystem into meaningful incremental revenue.

For ARK watchers, the bigger signal is the growing allocation toward genomics and biotech as Wood searches for the next major innovation cycle.